sever
acut
respiratori
syndrom
sar
epidem
origin
china
caus
previous
uncharacter
coronaviru
could
identifi
specif
rtpcr
amplif
effort
control
futur
sar
outbreak
depend
accur
earli
identif
sarscov
infect
patient
realtim
fluorogen
rtpcr
assay
base
noncod
region
ncr
sarscov
genom
develop
quantit
sar
diagnost
tool
ideal
amplif
effici
sensit
sarscov
rtpcr
assay
yield
e
valu
pcr
product
concentr
increas
per
amplif
cycl
equal
demonstr
ncr
sarscov
base
rtpcr
reaction
could
formul
reach
excel
e
valu
amplif
efficaci
sarscov
cdna
prepar
deriv
viral
rna
extract
clone
recombin
plasmid
exhibit
ident
amplif
characterist
ie
amplif
efficaci
use
pcr
formul
develop
studi
viral
genom
copi
genom
equival
ge
per
infecti
unit
gepfu
sarscov
use
studi
also
establish
approxim
assay
detect
sensit
could
reach
pfu
ge
per
assay
preliminarili
demonstr
assay
could
effici
detect
sarscov
clinic
specimen
sar
probabl
suspect
patient
identifi
taiwan
ncr
base
sarscov
assay
demonstr
diagnost
specif
test
sampl
patient
acut
respiratori
diseas
nonsar
epidem
region
sever
acut
respiratori
syndrom
sar
newli
recogn
infecti
diseas
signific
health
econom
impact
worldwid
sar
initi
identifi
guangdong
provinc
china
novemb
subsequ
hong
kong
singapor
vietnam
taiwan
countri
europ
north
america
march
april
cdc
mmwr
lee
et
al
cdc
mmwr
riley
et
al
sar
epidem
caus
previous
uncharacter
coronaviru
sarscov
peiri
et
al
drosten
et
al
ksiazek
et
al
typic
coronaviru
particl
readili
visibl
electron
microscop
specif
coronaviru
sequenc
detect
revers
transcript
polymeras
chain
reaction
rtpcr
sarscov
infect
patient
peiri
et
al
drosten
et
al
lawrenc
sarscov
could
isol
cultiv
sputum
specimen
respiratori
secret
sar
patient
use
vero
cell
cultur
appear
sarsspecif
antibodi
serum
averag
day
follow
exposur
peiri
et
al
booth
et
al
incub
period
sar
rang
day
though
viremia
document
approxim
day
follow
exposur
challeng
earli
detect
sarscov
infect
low
viremia
infect
patient
low
viremia
yield
low
modest
specif
signalnois
ratio
make
distinct
earlyinfect
victim
nonsar
febril
patient
difficult
initi
effort
control
sar
direct
toward
identif
travelassoci
case
origin
china
sar
epidem
area
hong
kong
riley
et
al
lipsitch
et
al
twu
et
al
despit
enorm
effort
implement
extens
control
measur
still
unrecogn
case
sar
led
nosocomi
cluster
subsequ
spread
healthcar
facil
commun
set
differ
region
world
twu
et
al
seto
et
al
sever
factor
might
contribut
difficulti
recogn
case
sar
earli
symptom
sar
nonspecif
commonli
associ
respiratori
ill
updat
interim
us
case
definit
sever
acut
respiratori
syndrom
sar
cdc
decemb
patient
sar
immunocompromis
chronic
condit
eg
diabet
mellitu
chronic
renal
insuffici
may
remain
afebril
acut
ill
symptom
attribut
underli
diseas
delay
sar
diagnosi
reappear
sar
toronto
canada
illustr
possibl
futur
outbreak
sar
might
occur
flu
season
differ
part
world
thu
would
adequ
reli
sole
preliminari
clinic
symptom
fever
cough
detect
differenti
sarscov
infect
common
upper
respiratori
infect
variou
rtpcr
test
detect
sarscov
avail
use
differ
sarscov
genom
sequenc
drosten
et
al
peiri
et
al
format
sarscov
rtpcr
assay
rang
convent
agaros
gel
base
assay
fluorogen
realtim
rtpcr
assay
realtim
rtpcr
may
prefer
format
due
simplic
abil
gener
quantit
data
howev
current
realtim
sarscov
rtpcr
assay
valid
document
consist
detect
sensit
specif
detect
low
sarscov
titer
earli
stage
ill
expect
characterist
sarscov
similar
rna
virus
flavivirus
high
rate
genet
mutat
lead
evolut
new
viral
variant
leitmey
et
al
mangada
igarashi
sanchez
ruiz
possibl
high
mutat
rate
sarscov
would
render
given
rtpcr
assay
useless
assay
target
sequenc
subject
mutat
chang
thu
neg
test
result
may
rule
sarscov
infect
especi
patient
show
earli
symptom
sar
studi
report
develop
realtim
rtpcr
assay
base
highli
conserv
ncr
genom
quantit
sar
diagnost
system
marra
et
al
ruan
et
al
retrospect
demonstr
assay
could
use
effici
diagnost
identifi
sarscov
posit
sampl
deriv
sar
probabl
suspect
patient
taiwan
sar
outbreak
sarscov
rna
cdna
prepar
sarscov
strain
use
studi
origin
deceas
physician
vietnam
us
cdc
isol
known
strain
urbani
rota
et
al
obtain
us
armi
medic
research
institut
infecti
diseas
fort
detrick
maryland
twenti
throat
swab
acut
respiratori
diseas
ard
patient
fort
jackson
south
carolina
obtain
collect
walter
reed
armi
institut
research
silver
spring
maryland
neg
control
sarscov
assay
mcneill
et
al
viral
rna
extract
transcrib
sarscov
cdna
revers
transcript
rt
reaction
use
commerci
rna
extract
kit
qiagen
inc
rt
kit
pe
appli
biosystem
inc
foster
citi
california
rna
mix
rt
reaction
mixtur
contain
antisens
sarscov
rt
primer
pmolreact
accord
manufactur
instruct
rt
mixtur
incub
follow
c
min
c
min
c
min
result
cdna
store
c
test
fluorogen
probeprim
pcr
condit
fluorogen
probe
famtttcatcgaggccacgcggagtamra
flank
primer
pair
sens
primer
antisens
primer
design
base
conserv
sarscov
ncr
canadian
isol
marra
et
al
genbank
access
purchas
pe
appli
biosystem
inc
foster
citi
california
pcr
master
mixtur
contain
follow
ingredi
abi
pcr
buffer
ii
mm
mgcl
mm
dntp
nm
upper
primer
nm
lower
primer
nm
fluorogen
taqman
probe
label
fam
report
dye
tamra
quencher
dye
unit
taq
dna
polymeras
amplitaq
gold
abi
foster
citi
california
two
microlit
viral
cdna
deriv
rt
reaction
mix
l
pcr
master
mixtur
pcrcdna
mixtur
subject
follow
amplif
condit
c
min
heat
activ
amplitaq
gold
enzym
cycl
c
c
two
commerci
avail
fluorogen
thermocycl
use
perform
realtim
rtpcr
assay
develop
report
rotorgen
realtim
pcr
thermocycl
westburg
bv
inc
leusden
netherland
mj
opticon
dna
engin
mj
inc
massachusett
construct
isol
recombin
plasmid
contain
sarscov
ncr
sens
antisens
primer
sarscov
use
gener
sarscov
cdna
cycl
pcr
amplif
sarscov
ncr
pcr
amplicon
clone
smai
site
vector
use
taclon
protocol
mezei
stort
ligat
vectorcdna
mixtur
transform
e
coli
host
one
recombin
plasmid
clone
identifi
xgal
neg
incub
overnight
c
select
lb
agar
plate
contain
ampicillin
adequ
xgal
iptg
substrat
plasmid
extract
purifi
modifi
alkalin
lysi
csclgradient
centrifug
ml
overnight
lb
broth
cultur
contain
mgml
ampicillin
assay
optim
explor
combin
assay
paramet
mg
concentr
flank
primersprob
ratio
concentr
anneal
temperatur
achiev
highest
possibl
detect
effici
sarscov
templat
optim
rt
pcr
assay
condit
obtain
describ
use
throughout
studi
variou
concentr
viral
rna
use
demonstr
quantit
natur
assay
fig
show
typic
sigmoid
plot
repres
format
sarscov
specif
pcr
product
sampl
deriv
vero
cell
cultur
contain
fivefold
sarscov
use
fluorogen
sarscov
ncr
base
rtpcr
system
sarscov
viral
stock
serial
dilut
dynam
rang
pfureact
use
gener
viral
cdna
demonstr
assay
copi
number
depend
reaction
well
contain
serial
dilut
viral
copi
number
ie
pfureact
yield
sequenti
sigmoid
curv
arrang
high
low
copi
number
left
right
well
nontempl
control
show
nois
background
assay
b
realtim
amplif
detect
clone
sarscov
ncr
use
fluorogen
sarscov
ncr
base
rtpcr
system
fivefold
serial
dilut
clone
sarscov
plasmid
gereact
use
demonstr
assay
copi
number
depend
reaction
well
contain
serial
dilut
yield
sequenti
sigmoid
curv
arrang
high
low
copi
number
left
right
figur
well
nontempl
control
show
nois
background
assay
serial
dilut
viral
rna
show
accumul
fluoresc
r
amplif
cycl
number
increas
threshold
cycl
c
concentr
cdna
defin
cycl
number
applic
softwar
detect
increas
product
fluoresc
calcul
background
fluoresc
holland
et
al
c
valu
describ
viral
cdna
concentr
automat
calcul
applic
softwar
intercept
fluoresc
signal
base
line
background
fluoresc
set
averag
test
sampl
cycl
parallel
sigmoid
plot
repres
serial
dilut
sarscov
cdna
templat
shown
display
sequenti
order
higher
concentr
templat
cdna
result
lower
c
valu
ie
greater
initi
viral
cdna
templat
copi
number
requir
fewer
amplif
cycl
smaller
c
valu
reach
detect
fluoresc
level
preliminari
result
demonstr
fluorogen
rtpcr
assay
capabl
detect
sarscov
viral
cdna
dosedepend
fashion
least
seven
serial
fivefold
dilut
log
dilut
addit
assay
also
capabl
discrimin
specif
sarscov
viral
stock
cdna
background
level
nontempl
control
show
fluoresc
signal
thu
far
sarscov
cdna
copi
standard
present
plaqueform
unit
pfu
use
studi
obtain
laboratori
deriv
sarscov
stock
live
sarscov
safe
use
clinic
laboratori
also
difficult
maintain
consist
viral
rna
standard
routin
usag
due
labil
natur
rna
molecul
therefor
recombin
plasmid
contain
noncod
sarscov
cdna
construct
serv
sarscov
genom
equival
standard
recombin
plasmid
contain
sarscov
noncod
region
construct
isol
possibl
sarscov
genom
refer
standard
see
section
fig
demonstr
plasmid
use
sarscov
genom
copi
number
standard
assay
develop
studi
c
valu
serial
dilut
plasmid
concentr
reflect
copi
number
depend
reaction
slope
standard
curv
ident
slope
sarscov
viral
standard
curv
see
fig
illustr
dna
viral
cdna
amplifi
method
amplif
efficaci
fig
comparison
quantit
sarscov
standard
curv
deriv
direct
viral
cdna
prepar
clone
ncr
sarscov
plasmid
dna
shown
standard
curv
yield
slope
two
parallel
line
taken
fig
b
gepfu
ratio
could
deriv
direct
readout
intercept
differ
gepfu
gepfu
ratio
also
calcul
intercept
differ
x
c
cycl
cycl
viral
cdna
pfu
clone
plasmid
ge
standard
curv
follow
gepfu
e
ideal
amplif
effici
given
doubl
helic
cdna
substrat
yield
twofold
increas
pcr
product
amplif
cycl
e
valu
pcr
product
increment
per
amplif
cycl
quantit
realtim
pcr
assay
estim
slope
standard
curv
consist
c
valu
serial
dilut
target
cdna
either
viral
cdna
prepar
clone
plasmid
may
use
purpos
shown
fig
sarscov
ncr
pcr
assay
consist
yield
standard
curv
slope
produc
e
valu
slope
amplif
effici
e
observ
e
ideal
demonstr
rtpcr
assay
amplif
effici
could
use
consist
detect
ion
sarscov
viral
rna
extract
sampl
contain
littl
pfu
per
reaction
anticip
c
valu
cycl
data
shown
fig
illustr
assay
could
use
detect
viral
cdna
prepar
well
clone
sarscov
ncr
amplif
efficaci
linear
regress
model
use
determin
number
infecti
unit
pfu
present
given
sarscov
prepar
result
calcul
indic
ratio
defect
infecti
particl
could
deduc
differ
standard
curv
assay
use
viral
cdna
prepar
well
clone
sarscov
ncr
gepfu
ratio
deriv
direct
readout
intercept
differ
gepfu
gepfu
ratio
calcul
intercept
differ
x
c
cycl
cycl
viral
cdna
pfu
clone
plasmid
ge
standard
curv
follow
gepfu
e
demonstr
util
sarsspecif
quantit
rtpcr
assay
diagnost
purpos
assay
use
quantit
detect
sarscov
nasopharyng
aspir
obtain
patient
diagnos
probabl
suspect
sar
case
use
clinic
criteria
assay
use
l
extract
aspir
wash
per
reaction
assay
set
run
cycl
amplif
cdcpc
sar
posit
control
rna
provid
taiwanes
cdc
blank
serv
neg
control
clone
templat
use
sarscov
ge
copi
control
base
gepfu
ration
cutoff
threshold
sar
neg
tabl
indic
assay
develop
studi
could
effici
detect
sarscov
infect
patient
taiwan
sarscov
rna
provid
center
diseas
control
cdc
ministri
health
taiwan
clone
use
posit
control
five
sampl
test
identifi
sarscov
posit
posit
rate
sar
identif
sarscov
rtpcr
posit
sampl
indic
presenc
low
concentr
viral
nucleic
acid
unfortun
laboratori
test
result
rise
sarsspecif
antibodi
sarscov
viral
isol
avail
corrobor
rtpcr
data
studi
investig
confirm
specif
sarscov
rtpcr
studi
twenti
clinic
sampl
deriv
acut
respiratori
diseas
ard
patient
caus
adenoviru
us
employ
neg
control
sarscov
assay
mcneill
et
al
none
ard
sampl
yield
posit
fluoresc
signal
sarscov
specif
sarscov
genom
sequenc
differ
significantli
known
coronavirus
particularli
ncr
marra
et
al
ruan
et
al
forti
ncr
sarscov
sequenc
deposit
genbank
databas
blast
search
demonstr
homolog
among
variou
sarscov
isol
obtain
differ
part
world
demonstr
ncr
base
fluorogoen
rtpcr
develop
studi
could
use
effici
diagnost
assay
laboratori
grown
sarscov
detect
quantif
preliminarili
illustr
assay
wide
dynam
rang
detect
log
excel
linear
linear
coeffici
greater
use
cdna
templat
deriv
serial
dilut
viral
rna
revers
transcript
rt
reaction
data
present
fig
show
detect
rang
sarscov
pfu
per
assay
c
valu
cycl
obtain
pfuassay
repres
ultim
end
point
assay
later
demonstr
end
point
lower
detect
limit
assay
could
reach
low
pfu
per
assay
c
valu
approxim
cycl
data
shown
clone
ncr
sarscov
cdna
also
establish
studi
molecular
copi
standard
genom
equival
standard
sarscov
assay
demonstr
studi
clone
cdna
could
mimic
viral
cdna
deriv
sarscov
rna
prepar
copi
number
standard
assay
fig
show
minim
detect
copi
number
two
ge
per
assay
c
valu
greater
cycl
howev
popul
size
clone
sarscov
standard
two
copi
per
reaction
small
repres
normal
distribut
gaussian
distribut
thu
multipl
repeat
assay
use
low
substrat
copi
number
two
copi
per
assay
would
yield
result
hit
miss
phenomenon
order
obtain
reproduc
result
assay
cutoff
end
point
assay
rais
ge
per
assay
c
valu
cycl
base
calcul
sarscov
gepfu
ratio
fig
actual
experiment
data
use
serial
dilut
viral
cdna
prepar
clone
lower
detect
limit
sarscov
assay
could
conserv
defin
pfu
ge
per
assay
tradit
express
viral
titer
plaqueform
unit
pfu
per
ml
must
determin
convent
viral
plaqu
assay
cultur
method
identifi
viabl
virus
gener
cytopath
effect
plaqu
confluent
lawn
suscept
host
cell
vero
cell
drosten
et
al
viral
plaqu
assay
use
score
total
viabl
virus
infect
host
cell
thu
use
distinguish
detect
viral
contamin
capabl
infect
host
cell
use
plaqu
assay
porterfield
de
madrid
porterfield
contrast
srarcov
rtpcr
assay
develop
studi
specif
sarscov
detect
howev
sarscov
pcr
assay
develop
studi
use
differenti
among
live
versu
dead
viral
particl
freeman
et
al
bae
et
al
mackay
et
al
viral
particl
genom
segment
contain
intact
pcr
target
sequenc
ncr
sarscov
would
detect
one
genom
equival
ge
differ
pfu
viabl
virus
ge
total
viral
count
includ
defect
function
virus
sarscov
mathemat
express
gepfu
ratio
freeman
et
al
bae
et
al
gepfu
ratio
approxim
studi
repres
gepfu
ratio
vero
cell
deriv
sarscov
stock
use
studi
find
high
gepfu
ratio
studi
support
hypothesi
sarscov
cultur
sarscov
infect
clinic
sampl
contain
infecti
defect
subgenom
viral
rna
ie
sarscov
infecti
unit
repres
multipl
viral
rna
speci
like
noncod
base
sarscov
rtpcr
assay
could
detect
infecti
defect
viral
rna
clinic
sampl
poon
et
al
possibl
viral
stock
differ
prepar
might
contain
pfu
per
ml
total
viral
particl
rna
copi
number
would
differ
bae
et
al
peccoud
jacob
pfu
infecti
activ
given
viral
stock
greatli
affect
percentag
viabl
viru
numer
factor
determin
affect
viabil
individu
viral
stock
cultur
condit
nutrient
ionic
strength
incub
time
temperatur
storag
condit
durat
temperatur
viral
harvest
condit
thu
difficult
obtain
univers
refer
viral
stock
contain
precis
standard
viral
copi
number
persist
viabil
data
demonstr
studi
clone
plasmid
could
use
replac
viral
cdna
stabl
ration
sarscov
copi
number
standard
sarscov
rtpcr
assay
practic
applic
sarscov
rtpcr
develop
studi
accur
identifi
sarscov
suspect
sar
patient
key
success
control
sar
outbreak
identifi
sarscov
infect
individu
earli
stage
infect
allow
public
health
offic
appli
adequ
physic
quarantin
measur
sar
infect
individu
becom
highli
contagi
requir
deploy
highli
sensit
sarscov
diagnost
detect
low
sarscov
titer
studi
assay
use
test
limit
number
total
rna
extract
deriv
sar
suspect
probabl
patient
taiwan
test
result
indic
feasibl
use
develop
assay
identifi
sarscov
infect
patient
viremia
load
rang
pfu
pfuml
even
though
limit
number
sampl
test
studi
assay
confirm
specif
ie
none
nonsar
ard
patient
sampl
test
posit
use
sarscov
assay
even
though
specif
inform
onset
date
diseas
clinic
sampl
test
studi
demonstr
noncod
base
rtpcr
develop
studi
could
use
detect
infecti
defect
viral
rna
thu
assay
fairli
high
diagnost
sensit
detect
sarscov
earli
stage
infect
previous
report
mean
time
onset
symptom
sampl
collect
rang
day
sarscov
detect
directli
nasopharyng
aspir
use
realtim
rtpcr
peiri
et
al
b
tsang
et
al
propos
verifi
valid
assay
develop
studi
use
care
select
panel
refer
sampl
consist
wide
dynam
rang
natur
infect
sar
sampl
ie
pfuml
well
sar
neg
control
sampl
howev
difficult
obtain
credibl
sar
refer
sampl
known
infecti
titer
sinc
known
major
outbreak
sar
last
multicountri
outbreak
conserv
ncr
featur
rna
virus
dengu
virus
report
util
develop
typespecif
rtpcr
assay
dengu
viru
identif
quantif
throughout
world
sudiro
et
al
sudiro
et
al
houng
et
al
houng
et
al
thu
would
reason
predict
ncr
base
sarscov
specif
rtpcr
assay
use
detect
differ
srascov
origin
outbreak
variou
geograph
origin
demonstr
sarscov
ncr
base
assay
use
canadian
sarscov
sequenc
could
use
detect
laboratori
grown
sarscov
urbani
strain
well
variou
sarscov
infect
sampl
taiwan
base
assay
excel
perform
capac
high
detect
sensit
pfuassay
robust
detect
sarscov
differ
origin
prepar
includ
direct
viral
cdna
well
clone
recombin
plasmid
superior
specif
specif
amplif
efficaci
shown
report
ncr
base
sarscov
rtpcr
abl
serv
effici
sarscov
diagnost
event
futur
outbreak
